Document is current

Article History

Received: 5 March 2025

Accepted: 29 April 2025

First Online: 8 July 2025

Declarations

:

: Stela Vujosevic: AbbVie, Inc., Alimera, Apellis Pharmaceuticals, Inc., Bayer, Boehringer Ingelheim, Novartis, RetinAI, Roche, Zeiss (consultancy fees). Ivana Gunderson: 4D Molecular Therapeutics, Inc., AbbVie, Inc., Alexion Pharmaceuticals, Inc., Annexon Biosciences, Apellis Pharmaceuticals, Inc., Boehringer Ingelheim Pharma GmbH & Co. KG., Cognition Therapeutics, Inc., Eyepoint Pharmaceuticals, Inc., F. Hoffman-La Roche Ltd, Genentech, Inc., IMA Group, Janssen Research & Development, LLC, Kyowa Kirin Co., Ltd., Stealth BioTherapeutics, Inc., The Lowy Medical Research Institute, Ltd, (financial support); Boehringer Ingelheim Pharma GmbH & Co. KG, F. Hoffman-La Roche Ltd, Ora, Inc (consultancy fees); Austin Clinical Research, LLC, Gunderson Research Consulting, LLC (personal financial interest). Asma Burale: Boehringer Ingelheim (consultancy fees). Ben Moody: None. Rebecca C. Stacy: Boehringer Ingelheim (employee). Martin Gliem: Boehringer Ingelheim International GmbH (employee).

: Market research does not require Institutional Review Board (IRB) approval because it falls outside the remit of the governance arrangements for research ethics committees. The market research conducted was carried out to understand behavior and opportunities and inform business decision-making. The project was conducted in line with local data protection laws and Market Research Society’s Code of Conduct, including British Healthcare Business Intelligence Association, European Society for Opinion and Market Research, European Pharmaceutical Market Research Association, and other relevant national codes of practice. No clinical assessments were undertaken as part of the project which would then necessitate IRB approval. The participants were selected independently of the sponsor and consented to participating in the market research project in line with standard market research guidelines.